Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): Follow-up results of a phase II study

Optimization and Characterization of a Sphingomyelin/Cholesterol Liposome Formulation of Vinorelbine with Promising Antitumor Activity

“…Recently, a sphingomyelin/cholesterol (SM/Chol) liposomal formulation of another vinca alkaloid, vincristine (VCR), has shown clinical promise in Phase II clinical trials against hematological malignancies. 15,16 Since the recommended dose of VRL in humans is relatively high (30 mg/m 2 vs. 1.4 mg/m 2 for VCR), a drug loading method that allows for relatively high drug-to-lipid (D/L) ratios was thought to be important to minimize lipid dosing. While each of the approved liposomal products used in oncology utilize pH-gradient or ammonium sulfate loading methods, an ionophore loading method has recently been described as an effective method for introducing lipophilic amines into liposomes to achieve high drug loading efficiencies.…”

Liposomal Nanomedicines: An Emerging Field

“…This formulation has been giving excellent results in studies comparing the efficacy of conventional CHOP (chemotherapy treatment composed of cyclophosphamide, doxorubicin, vincristine, and prednisone) and CHOP in which the vincristine has been replaced by LN-vincristine (Rodriguez et al, 2002;Rodriguez et al, 2004). Thus, in a study focused on the treatment of non-Hodgkin's lymphoma in elderly patients, LN-vincristine CHOP + rituxan (Rodriguez et al, 2004) was compared to CHOP + rituxan (Coiffier et al, 2002), and the overall response for the former study was 93% compared to 83% for the latter.…”

“…Formulations with half-lives of release of 8.7 hours and 117 hours had greatly reduced efficacy. Fortuitously, this drug-to-lipid ratio is very close to the value chosen for the formulation that has undergone the greatest degree of clinical testing for a liposomal version of this drug (Sarris et al, 2000;Rodriguez et al, 2002;Rodriguez et al, 2004).…”

“…Thus, in a study focused on the treatment of non-Hodgkin's lymphoma in elderly patients, LN-vincristine CHOP + rituxan (Rodriguez et al, 2004) was compared to CHOP + rituxan (Coiffier et al, 2002), and the overall response for the former study was 93% compared to 83% for the latter. The overall survival at 22 to 24 months was 98% for the former treatment and 70% for the latter.…”

Nanotechnology-based approaches in anticancer research

“…74 This formulation has given excellent results in studies comparing the efficacy of conventional CHOP (chemotherapy treatment composed of cyclophosphamide, doxorubicin, vincristine, and prednisone) and CHOP in which the vincristine has been replaced by LNP-vincristine. 75,76 Moreover, increased drug retention of vincristine has been reported to be related to increased drug:lipid ratios. 75 Lipid-based nanocapsules have given a novel approach to scientific communities for encapsulation of poorly soluble drugs like cisplatin.…”